Is There a Generic for Emrosi?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Emrosi (minocycline). The Orange Book shows its last listed patent expires January 7, 2039 and its last listed exclusivity ends November 1, 2027.

Run it in Rivvi

Map Emrosi and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Emrosi products in the Orange Book

Emrosi products and approved generics
Form and route	Strength	Brand status	Brand TE	Active generics	Generic TE codes
capsule, extended release, oral	EQ 40MG BASE	Marketed (Rx)	None	0	None

NDA 219015, held by JOURNEY MEDICAL CORP. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Emrosi patents

Patents listed for Emrosi
Patent	Expires	Covers	Use code	NDA
11364212	January 7, 2039	Method of use	U-4043	219015
11191740	January 7, 2039	Method of use	U-4043	219015
10905664	January 7, 2039	Method of use	U-4043	219015
12594252	January 7, 2039	Method of use	U-4043	219015

Emrosi exclusivity

Exclusivity listed for Emrosi
Code	Meaning	Expires	NDA
NP	New product	November 1, 2027	219015

Emrosi NDC codes

69489-131

Questions

Is there a generic for Emrosi?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Emrosi (minocycline). The Orange Book shows its last listed patent expires January 7, 2039 and its last listed exclusivity ends November 1, 2027.

What is the generic name for Emrosi?

The active ingredient in Emrosi is minocycline, per the FDA Orange Book.

When does the Emrosi patent expire?

The last patent listed for Emrosi in the Orange Book expires January 7, 2039. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.